<i>In Vivo</i>
            Magnetic Resonance Imaging of Orthotopic Prostate Cancer

Ravoori, Murali; Singh, Shailbala; Yang, Peiying; Wei, Wei; Chen, Huiqin; Ma, Jingfei; Bankson, James A.; Kundra, Vikas

doi:10.2144/btn-2020-0021

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultrasound is an optimal imaging modality to monitor orthotopic prostate tumor growth ( 20 ). The advantages of ultrasound compared to MRI and bioluminescence include low cost, convenience and real time imaging, and ultrasound allows the clear delineation of orthotopic tumors from the surrounding tissues ( 12 , 21 ). CEUS has been applied in the imaging of tumors in orthotopic prostate cancer xenograft mouse models, showing orthotopic tumors are highly vascularized ( 20 , 22 ).…”

Section: Discussionmentioning

confidence: 99%

Comparison of tumor angiogenesis in subcutaneous and orthotopic LNCaP mouse models using contrast-enhanced ultrasound imaging

Liu¹,

Zhu²,

Ye³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Understanding angiogenesis in prostate cancer is essential. LNCaP prostate xenograft tumors are androgen responsive and closely mimic clinical disease. Orthotopic animal models replicate aspects of the cancer microenvironment and are more clinically relevant than subcutaneous models.Comparative studies investigating angiogenesis using contrast-enhanced ultrasound (CEUS) imaging in subcutaneous and orthotopic mouse models of prostate cancer have not been performed.Methods: Tumor microcirculation and perfusion in subcutaneous and orthotopic LNCaP xenograft Balb/c athymic nude mice models were compared by investigating microbubble wash-in with CEUS. Results:The take rate of subcutaneous and orthotopic tumors were 58.3% and 68.2%, respectively.On CEUS, orthotopic prostate tumors enhanced more rapidly than subcutaneous tumors. Mean arrivaltime (Atm) for subcutaneous tumors, orthotopic prostate tumors, and kidney were 4.21±1.86, 1.72±0.79, and 0.73±0.12 s, respectively. Mean Atm was significantly longer for subcutaneous tumors compared to orthotopic prostate tumors or kidney (P<0.01). Mean time to peak enhancement (TtoPk) for subcutaneous tumors, orthotopic prostate tumors, and kidney were 38.56±13.23, 12.39±7.17, and 3.74±1.41 s, respectively. Mean TtoPk were significantly shorter for orthotopic prostate tumors and kidney compared to subcutaneous tumors (P<0.01). Mean wash-in area under the curve (WiAuC) for subcutaneous tumors, orthotopic

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of tumor angiogenesis in subcutaneous and orthotopic LNCaP mouse models using contrast-enhanced ultrasound imaging

Liu¹,

Zhu²,

Ye³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Established modalities that reveal and evaluate the occurrence of BCa within murine models include bioluminescence imaging (BLI), micro-ultrasound imaging (MUI), magnetic resonance imaging (MRI), and positron emission tomography (PET), as summarized in Table 1 . These modalities have provided a better understanding and visualization of cancer development [ 28 ], early detection [ 29 ], and therapeutic efficacy [ 30 , 31 , 32 ] in cancers such as breast [ 29 , 31 , 32 ], prostate [ 33 ], colon [ 28 ], and lung [ 30 ]. BLI relies on the biochemical generation of light for tumor assessment while PET utilizes radiotracers to investigate tumor burden while also providing information on the metabolic and biochemical functions.…”

Section: Requirement Of Non-invasive Imaging Modalities To Confirm An...mentioning

confidence: 99%

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

Relouw

Dugbartey

Şener

2023

Cancers

View full text Add to dashboard Cite

Bladder cancer (BCa) is the sixth most prevalent cancer in men and seventeenth most prevalent cancer in women worldwide. Current treatment paradigms have limited therapeutic impact, suggesting an urgent need for the investigation of novel therapies. To best emulate the progression of human BCa, a pre-clinical intravesical murine model is required in conjunction with existing non-invasive imaging modalities to detect and evaluate cancer progression. Non-invasive imaging modalities reduce the number of required experimental models while allowing for longitudinal studies of novel therapies to investigate long-term efficacy. In this review, we discuss the individual and multi-modal use of non-invasive imaging modalities; bioluminescence imaging (BLI), micro-ultrasound imaging (MUI), magnetic resonance imaging (MRI), and positron emission tomography (PET) in BCa evaluation. We also provide an update on the potential and the future directions of imaging modalities in relation to intravesical murine models of BCa.

show abstract

In Vivo Magnetic Resonance Imaging of Orthotopic Prostate Cancer

Cited by 2 publications

References 33 publications

Comparison of tumor angiogenesis in subcutaneous and orthotopic LNCaP mouse models using contrast-enhanced ultrasound imaging

Comparison of tumor angiogenesis in subcutaneous and orthotopic LNCaP mouse models using contrast-enhanced ultrasound imaging

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

Contact Info

Product

Resources

About